Established in April, 20 15, jiyinga has established medical laboratories, genetic research institutes, medical device industrialization bases and other entities in Beijing, Suzhou and Shenzhen, with more than 700 employees and a business area of13000m2.
The company has the qualifications of national professional and innovative "Little Giant" enterprise, academician expert workstation, postdoctoral research center, Beijing scientific and technological enterprise research and development institution and national high-tech enterprise. It has formed two domestic platforms, NGS detection and tumor gene big data, supporting four business segments, namely clinical detection, medical device manufacturing, scientific and technological cooperation and tumor prevention, and is committed to becoming the most reliable tumor gene big data service platform.
The CEO of the company is a doctor, senior engineer and doctoral supervisor of Beijing Institute of Genomics, Chinese Academy of Sciences. He has been engaged in scientific research in the fields of genome medicine and translational medicine 10 for more than 0 years, intensively cultivated in the field of tumor precision medicine, presided over 6 research projects (topics), and won the excellent titles of national talents and leading talents in science and technology for many times, with 49 patents. He has published more than 70 SCI papers in authoritative journals such as Science, Nature and NG, which is influential.